15 research outputs found
Factors influencing the time to surgery after neoadjuvant chemotherapy in breast cancer patients
Purpose
It is suspected that delayed surgery after neoadjuvant chemotherapy (NACT) leads to a worse outcome in breast cancer patients. We therefore evaluated possible influencing factors of the time interval between the end of NACT and surgery.
Methods
All patients receiving NACT due to newly diagnosed breast cancer from 2015 to 2017 at the Department of Gynecology, Saarland University Medical Center, were included. The time interval between end of NACT and surgery was defined as primary endpoint. Possible delaying factors were investigated: age, study participation, outpatient and inpatient presentations, implants/expander, MRI preoperatively, discontinuation of chemotherapy, and genetic mutations.
Results
Data of 139 patients was analyzed. Median age was 53 years (22–78). The time interval between end of NACT and surgery was 28 days (9–57). Additional clinical presentations on outpatient basis added 2 days (p = 0.002) and on inpatient basis added 7 days to time to surgery (p < 0.001). Discontinuation of NACT due to chemotherapy side effects prolonged time to surgery by 8 days (p < 0.001), whereas discontinuation due to disease progress did not delay surgery (p = 0.6). In contrast, a proven genetic mutation shortened time to surgery by 7 days (p < 0.001). Patient’s age, participation in clinical studies, oncoplastic surgery, and preoperative MRI scans did not delay surgery.
Conclusion
Breast care centers should emphasize a reduction of clinical presentations and a good control of chemotherapy side effects for breast cancer patients to avoid delays of surgery after NACT
Uterine Leiomyosarcoma
Uterine leiomyosarcoma (uLMS) is a rare entity among
malignant gynecologic tumors with a very unfavorable
prognosis and the highest prevalence in the pre- and
peri-menopause. Only early-stage tumors have an acceptable prognosis, provided the patient has been treated
without injuring the uterus. uLMS is often diagnosed accidentally and the correct diagnosis ishampered by
equivocal features similar to the far more frequent benign uterine fibroids. Surgery is the basis of therapy, and
it should be done in order to remove the uterus intact. As
vaginal, abdominal, and endoscopic surgery – possibly
including morcellation – are the methods of choice for
the treatment of uterine fibroids, pre-operatively undiagnosed leiomyosarcoma detected by pathologic examination will have a worsened prognosis. Systemic treatment
and radiotherapy are of no proven value in the adjuvant
setting. Thus, there is strong need for a reliable pre-operative risk score for leiomyosarcoma in order to justify diagnostic means beyond clinical routine and to choose the
correct surgical pathway. The clinical problems in the diagnosis of leiomyosarcoma and treatment are exemplified by a case report of a 30-year-old childless patient.
Diagnostic tools as well as treatment options in adjuvant
and palliative situations are reviewed
Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study
Background: Treatment of postmenopausal, hormone receptor-positive metastatic breast cancer (MBC) patients varies despite clear therapy guidelines, favoring endocrine treatment (ET). Aim of this study was to analyze persistence of palliative aromatase inhibitor (AI) monotherapy in MBC patients.
Methods: EvAluate-TM is a prospective, multicenter, noninterventional study to evaluate treatment with letrozole in postmenopausal women with hormone receptor–positive breast cancer. To assess therapy persistence, defined as the time from therapy start to the end of the therapy (TTEOT), two pre-specified study visits took place after 6 and 12 months. Competing risk survival analyses were performed to identify patient and tumor characteristics that predict TTEOT.
Results: Out of 200 patients, 66 patients terminated treatment prematurely, 26 (13%) of them due to causes other than disease progression. Persistence rate for reasons other than progression at 12 months was 77.7%. Persistence was lower in patients who reported any adverse event (AE) in the first 30 days of ET (89.5% with no AE and 56% with AE). Furthermore, patients had a lower persistence if they reported compliance problems in the past before letrozole treatment.
Conclusions: Despite suffering from a life-threatening disease, AEs of an AI will result in a relevant number of treatment terminations that are not related to progression. Some subgroups of patients have very low persistence rates. Especially with regard to novel endocrine combination therapies, these data imply that some groups of patients will need special attention to guide them through the therapy process.
Trial registration Clinical Trials Number: CFEM345DDE1
Uterine Leiomyosarcoma
Uterine leiomyosarcoma (uLMS) is a rare entity among
malignant gynecologic tumors with a very unfavorable
prognosis and the highest prevalence in the pre- and
peri-menopause. Only early-stage tumors have an acceptable prognosis, provided the patient has been treated
without injuring the uterus. uLMS is often diagnosed accidentally and the correct diagnosis ishampered by
equivocal features similar to the far more frequent benign uterine fibroids. Surgery is the basis of therapy, and
it should be done in order to remove the uterus intact. As
vaginal, abdominal, and endoscopic surgery – possibly
including morcellation – are the methods of choice for
the treatment of uterine fibroids, pre-operatively undiagnosed leiomyosarcoma detected by pathologic examination will have a worsened prognosis. Systemic treatment
and radiotherapy are of no proven value in the adjuvant
setting. Thus, there is strong need for a reliable pre-operative risk score for leiomyosarcoma in order to justify diagnostic means beyond clinical routine and to choose the
correct surgical pathway. The clinical problems in the diagnosis of leiomyosarcoma and treatment are exemplified by a case report of a 30-year-old childless patient.
Diagnostic tools as well as treatment options in adjuvant
and palliative situations are reviewed
Uterine Leiomyosarcoma
Uterine leiomyosarcoma (uLMS) is a rare entity among
malignant gynecologic tumors with a very unfavorable
prognosis and the highest prevalence in the pre- and
peri-menopause. Only early-stage tumors have an acceptable prognosis, provided the patient has been treated
without injuring the uterus. uLMS is often diagnosed accidentally and the correct diagnosis ishampered by
equivocal features similar to the far more frequent benign uterine fibroids. Surgery is the basis of therapy, and
it should be done in order to remove the uterus intact. As
vaginal, abdominal, and endoscopic surgery – possibly
including morcellation – are the methods of choice for
the treatment of uterine fibroids, pre-operatively undiagnosed leiomyosarcoma detected by pathologic examination will have a worsened prognosis. Systemic treatment
and radiotherapy are of no proven value in the adjuvant
setting. Thus, there is strong need for a reliable pre-operative risk score for leiomyosarcoma in order to justify diagnostic means beyond clinical routine and to choose the
correct surgical pathway. The clinical problems in the diagnosis of leiomyosarcoma and treatment are exemplified by a case report of a 30-year-old childless patient.
Diagnostic tools as well as treatment options in adjuvant
and palliative situations are reviewed
A Metastasis of Ovarian Cancer in the Bartholin Gland: A Case Report with Systematic Literature Review
The metastasis of a gynecological malignancy to the Bartholin gland is rare. We report the case of a 62-year-old patient
who had undergone extensive treatment of metastatic ovarian cancer that involved the liver, spleen, and peritoneum. She
presented with painful swelling of the left vulva. Clinical and sonographic examinations showed a solid tumor in loco typico
of the Bartholin gland. Surgical excision was performed. The patient died 3 months after the diagnosis of this metastasis.
We performed a systematic search of PubMed, which yielded 453 entries. We selected those with at least an abstract available in English that described metastatic lesions on the Bartholin gland (n=5). The review showed that a variety of primary
cancers (colorectal, medullary thyroid, breast cancer, and endometrial cancers) metastasize to this location. Some patients
showed signs of visceral metastasis. Bartholin gland metastases appeared as initial and metachronous manifestations. Most
patients were symptomatic, with painful swelling or abscess. Genetic alterations were mentioned in some cases. The main
pathways of metastasis discussed were lymphatic, but the mechanism of such metastasis remains unclear. Surgical resection was the preferred treatment option. The literature review indicated that Bartholin gland metastasis of ovarian cancer is
rare and associated with poor prognosis. Oncological reasons for vulvar pathologies should be taken into consideration in
patients with metastases
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study
Background. Breast cancer patients often use complementary and alternative medicine, but few prospectively collected data on the topic are available specifically for postmenopausal breast cancer patients. A large prospective study was therefore conducted within a noninterventional study in order to identify the characteristics of patients interested in integrative medicine. Methods. The EvAluate-TM study is a prospective, multicenter noninterventional study in which treatment with the aromatase inhibitor letrozole was evaluated in postmenopausal women with hormone receptor-positive primary breast cancer. Between 2008 and 2009, 5045 postmenopausal patients were enrolled at 339 certified breast centers in Germany. As part of the data collection process, patients were asked at the baseline about their interest in and information needs relating to integrative medicine. Results. Of the 5045 patients recruited, 3411 responded to the questionnaire on integrative medicine and took part in the analysis, 1583 patients expressed an interest in integrative medicine, and 1828 patients declared no interest. Relevant predictors of interest in integrative medicine were age, body mass index, tumor size, previous chemotherapy, and use of concomitant medications for other medical conditions. Interest in integrative medicine declined highly significantly (P 65 years, 38.0%). Patients in favor of integrative medicine were significantly less satisfied with the information received about individual treatments and antihormonal therapy. Patients with interest in integrative medicine were more often interested in rehabilitation and fitness, nutritional counseling, and additional support from self-help organizations. These women were mostly interested in receiving information about their disease and integrative medicine from a physician, rather than from other sources. Conclusions. This study shows that a considerable proportion of postmenopausal breast cancer patients are interested in integrative medicine. Information about integrative medicine should therefore be provided as part of patient care for this group. It was found that receiving concomitant medication for other medical conditions is one of the main predictors for women not being interested in integrative medicine. This group of patients may need special attention and individualized information about integrative medicine. Additionally, most patients were interested in obtaining the relevant information from their doctor
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study
Background: Decision-making for or against neoadjuvant or adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear guidelines, and some patients may unnecessarily undergo chemotherapy and be exposed to the associated toxicity. The aim of this study was to identify the patient population for whom this issue may bear relevance. Methods: Patients being treated with letrozole in the prospective multicenter noninterventional EvAluate-TM study were recruited. The percentage of patients receiving chemotherapy and factors associated with chemotherapy administration were identified. Results: In all, 3,924 (37.4%) patients received chemotherapy before treatment with letrozole. Of these, 293 (20%) underwent neoadjuvant therapy. Younger age was predictive for both adjuvant and neoadjuvant therapy. Overall, decisions in favor of administering chemotherapy are more likely to be made in patients with a higher body mass index (BMI), and neoadjuvant chemotherapy is administered at a higher rate in women with a lower BMI. Concomitant medication influenced the overall decision-making regarding chemotherapy, irrespective of whether it was given on a neoadjuvant or adjuvant basis. Conclusion: There is an ongoing debate as to whether all of the many patients who receive chemotherapy actually benefit from it. Neoadjuvant chemotherapy is frequently administered in this patient population, and this should encourage further research to resolve current clinical and research issues. (C) 2016 S. Karger GmbH, Freibur